Perceptive Advisors Poised to Benefit from Biopharma IPO

The health care-focused hedge fund firm plans to add to its stake when Kodiak Sciences goes public next week.

Joseph Edelman, chief executive officer of Perceptive Advisors (Chris Goodney/Bloomberg)

Joseph Edelman, chief executive officer of Perceptive Advisors

(Chris Goodney/Bloomberg)

It may not be one of those hot-shot internet unicorns, but when Kodiak Sciences goes public — possibly next Wednesday — at least one hedge fund firm stands to benefit in a big way.

Joseph Edelman’s Perceptive Advisors is an investor in the development-stage biopharmaceutical company, which on Monday set in motion its initial public offering (IPO), announcing in a new regulatory filing that it plans to offer 9 million shares for between $13 and $15 per share.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Related